Rectal Indomethacin and Sublingual Nitrates in prevention of post ERCP pancreatitis

Effect of Rectal Indomethacin and Nitroglycerin in Comparison with Rectal Indomethacin in the Prevention of post Endoscopic Retrograde Cholangio Pancreatography (ERCP) Pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161205031252N5

Enrollment

324

Registered

2018-01-18

Start date

2016-06-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ERCP-induced pancreatitis. Other acute pancreatitis

Interventions

Intervention 1: Intervention group: Indomethacin suppository, 100 mg, single dose, before ERCP plus nitroglycerin tablet, 0.4 mg, single sublingual, immediately after ERCP. Intervention 2: Control gro

Treatment - Drugs

Placebo

Intervention group: Indomethacin suppository, 100 mg, single dose, before ERCP plus nitroglycerin tablet, 0.4 mg, single sublingual, immediately after ERCP

Control group: Indomethacin suppository, 100 mg, single dose, before ERCP plus placebo tablet, single dose, sublingual, immediately after ERCP

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: aged 18-70 Need for ERCP

Exclusion criteria

Exclusion criteria: Contraindications of nitroglycerin Contraindications of Indomethacin Pregnancy Lactation

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: 24 hours after ERCP. Method of measurement: Serum levels of pancreatic enzymes.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Hormati

Ghoum University of Medical Sciences

Hormatia@muq.ac.ir+98 25 3612 2053

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026